Business Context and Reporting Period
This Form 8-K is a current report filed by Cerulean Pharma Inc. (not Dare Bioscience, Inc., as indicated in the metadata request) on June 26, 2015. The filing primarily addresses corporate governance changes, specifically the appointment of a Principal Accounting Officer and an amendment to a consulting agreement. The document was signed on May 27, 2016, indicating a delayed filing or a report covering events up to that date.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel appointments and contract amendments.
Material Changes
- Appointment of Principal Accounting Officer: On June 26, 2015, James E. O'Neill was appointed as Assistant Treasurer and Principal Accounting Officer. He concurrently serves as Controller, a role he has held since September 2014.
- Consulting Agreement Extension: On May 27, 2016, the Company amended its Consulting Agreement with Danforth Advisors, LLC. The term was extended by one year through May 26, 2017. This agreement covers strategic and financial advice, including services provided by Gregg Beloff as Interim Chief Financial Officer.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, management commentary on business performance, or specific risk factors. The document is limited to reporting the administrative changes listed above.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Dare Bioscience, Inc.") and the actual registrant ("Cerulean Pharma Inc.").
- Confirm the current status of Gregg Beloff as Interim CFO and the terms of the Danforth Advisors engagement.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Investigate the reason for the filing date (June 26, 2015) differing from the signature date (May 27, 2016).